Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

MLA

James L Gulley, et al. “Avelumab as Second-Line Therapy for Metastatic, Platinum-Treated Urothelial Carcinoma in the Phase Ib JAVELIN Solid Tumor Study: 2-Year Updated Efficacy and Safety Analysis.” Journal for ImmunoTherapy of Cancer, vol. 8, no. 2, Oct. 2020. EBSCOhost, https://doi.org/10.1136/jitc-2020-001246.

APA

James L Gulley, Manish R Patel, Keun-Wook Lee, Luc Dirix, Mary Ruisi, Jeffrey R Infante, Patrick Schöffski, Alain Ravaud, Ding Wang, Andrea B Apolo, John A Ellerton, Manish Agrawal, Michael S Gordon, Raid Aljumaily, Theodore Gourdin, Matthew H Taylor, Juliane Manitz, & Gregory Pennock. (2020). Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. Journal for ImmunoTherapy of Cancer, 8(2). https://doi.org/10.1136/jitc-2020-001246

Chicago

James L Gulley, Manish R Patel, Keun-Wook Lee, Luc Dirix, Mary Ruisi, Jeffrey R Infante, Patrick Schöffski, et al. 2020. “Avelumab as Second-Line Therapy for Metastatic, Platinum-Treated Urothelial Carcinoma in the Phase Ib JAVELIN Solid Tumor Study: 2-Year Updated Efficacy and Safety Analysis.” Journal for ImmunoTherapy of Cancer 8 (2). doi:10.1136/jitc-2020-001246.